Literature DB >> 1692865

Antigenic link between human interferons-alpha and -beta: the common epitope 1.

P Kontsek1, L Borecký, E Kontseková, M Novák, V Krchnák.   

Abstract

An until now unobserved consistent antigenic structure, tentatively named "common epitope 1," was detected on molecules of human recombinant (rHu) IFN-alpha 2 and natural HuIFN-beta by testing with monoclonal and polyclonal antibodies. The monoclonal antibody B6, obtained after immunization of BALB/c mice with human fibroblast IFN-beta, was capable of binding and neutralizing both IFN-alpha 2 and natural IFN-beta. The neutralizing activity of monoclonal antibody B6 was completely inhibited by a synthetic hexapeptide which corresponded to the amino acid sequence of IFN-alpha 2 in positions 132-137. Although a corresponding sequence of amino acids in the IFN-beta molecule was localized to the region 134-139 and shows only a 66% homology with the assumed IFN-alpha 2 binding site, lysine at position 132 in IFN-alpha 2 and at position 134 in IFN-beta seems to be crucial for establishment of the common epitope. Its existence was supported by experiments using polyclonal antibodies. Antiserum to IFN-alpha 2 showed cross-neutralization with IFN-beta, and vice versa, antiserum to IFN-beta cross-reacted with IFN-alpha 2. The ability for cross-neutralization by both polyclonal antisera was abolished in the presence of IFN-alpha 2 hexapeptide SH 132-137. No cross-reacting epitope could be detected on the IFN-alpha 1 molecule. These findings are the first evidence of a homology between human IFNs of alpha and beta types at the antigenic level. They indicate that the antigenic distinction between IFNs of alpha and beta types is not absolute.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692865     DOI: 10.1089/jir.1990.10.119

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  1 in total

Review 1.  Human natural interferon-alpha producing cells.

Authors:  P Fitzgerald-Bocarsly
Journal:  Pharmacol Ther       Date:  1993-10       Impact factor: 12.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.